SUBSCRIBE
SUBSCRIBE

Maxygen, Inc. Says Drug Under Amgen Patent Cloud

June 13, 2008 | 
1 min read

BANGALORE, June 13 (Reuters) - Shares of biotechnology firm Maxygen Inc slid as much as 30 percent after news that it could face a legal patent battle with sector leader Amgen Inc over its lead cancer drug.

Asia
Amgen
MORE ON THIS TOPIC
Facade of AstraZeneca's office in Shanghai, China
Mergers & acquisitions
AstraZeneca Buys FibroGen’s China Unit for $160M as Probes Continue
February 20, 2025
 · 
2 min read
 · 
Tristan Manalac
Trendy halftone business concept collage. Idea concept, business concept, financial planning,financial profit, favorable conditions, favorable conditions. Trendy modern retro illustration in bright trendy colors. Vector illustration
Mergers & acquisitions
Bain Bets Big on Japanese Market With $3.3B Tanabe Buy
February 10, 2025
 · 
1 min read
 · 
Tristan Manalac
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
Rare diseases
AceLink’s Fabry Hopeful Shows Potential in Mid-Stage Study
February 10, 2025
 · 
2 min read
 · 
Tristan Manalac
vial of vaccine for the vaccination plan against diseases in the China. Doctor with a vial with doses of the vaccine in front of the China flag
Earnings
Merck’s Gardasil Woes Grow as China Trade War Heats Up
February 4, 2025
 · 
4 min read
 · 
Annalee Armstrong